NIH Chemical Genomics Center (NCGC)

Overview

The NIH Chemical Genomics Center (NCGC) was created in 2008 as a Comprehensive Screening Center in the Molecular Libraries Probe Production Centers Network (MLPCN), part of the NIH Molecular Libraries Common Fund Program [commonfund.nih.gov]. The original goals of the NCGC were to to translate the discoveries of the Human Genome Project into biological and disease insights and ultimately new therapeutics for human disease through small molecule assay development, high-throughput screening, cheminformatics, and chemistry. Over the last several years the Tox21 program and the NIH RNAi screening program were added to the NCGC. In 2009, NIH announced the Therapeutics for Rare and Neglected Diseases (TRND). In 2010, NCGC and TRND were united to form the NIH Center for Translational Therapeutics.

The NCTT continues the mission of the NCGC. The multidisciplinary and collaborative approaches are the cornerstone of the Center. The NCGC is still referred to in the MLP, but please note that the original functions of NCGC are now in the NCTT Probe Development Branch. The Tox21 and RNAi programs are in the Chemical Genomic Branch. The TRND program is in the Therapeutics Development Branch. (See: Organization).

See all related projects for the NIH Chemical Genomics Center (NCGC) Program

Last Updated: August 19, 2011